ArticleJB & JS open access
A Sequential Approach to the Management of Posterior Glenoid Defects in RSA: Angulated BIO Versus Multiple Bioresorbable Pinning-Assisted Structural Bone-Grafting.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Surgical decisions on implant-related parameters can enhance knowledge transfer for glenoid bone grafting in primary reverse shoulder arthroplasty: a scoping review of heterogeneity sources.EFORT open reviews · 2024Article
- Large Glenoid Defects Treated by Multiple Bioresorbable Pinning-Assisted Bone-Grafting in Reverse Shoulder Arthroplasty.JBJS essential surgical techniquesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large posterior glenoid defects pose problems in reverse shoulder arthroplasty (RSA). We have adopted a sequential approach to the management of posterior glenoid defects using asymmetrical reaming, the placement of a ring graft around the central peg (bony-increased offset, or BIO), or structural bone-grafting, depending on the amount of glenoid retroversion. Furthermore, we have devised multiple bioresorbable pinning (MBP)-assisted bone-grafting, in which as many bioresorbable pins as required are inserted, from whichever aspects of the graft necessary, to achieve initial stability.
methodsWe reviewed 52 shoulders with posterior glenoid defects undergoing RSA between 2014 and 2019 (mean follow-up, 4.8 years; range, 2 to 6 years). Twenty (38.5%) of the shoulders had glenoid retroversion of <15° and were treated by asymmetrical reaming (Group A), 19 (36.5%) of the shoulders had retroversion of ≥15° to <30° and were treated with asymmetrical reaming combined with angulated ring graft around the central peg (Group B), and 13 (25.0%) of the shoulders had retroversion of ≥30° and were treated with MBP-assisted bone-grafting (Group C).
resultsMean version correction was 10.6° ± 4.3° in Group A, 20.7° ± 8.8° in Group B, and 33.8° ± 9.6° in Group C. The mean postoperative active anterior elevation was 138.3° ± 12.3°, 128.3° ± 12.3°, and 126.5° ± 15.3° in the 3 groups, respectively. The mean postoperative Constant score was 66.8 ± 14.6, 62.2 ± 13.5, and 61.7 ± 16.7, respectively. The mean preoperative active anterior elevation was significantly higher in Group A than in Group C (p = 0.037). The full or partial graft-incorporation rate (≥25% of original size) was 89.5% in Group B and 100% in Group C. One glenoid fracture and 1 case of transient brachial plexus palsy occurred in Group B (10.5%), and 1 acromion fracture and 2 cases of transient brachial plexus palsy occurred in Group C (23.1%).
conclusionsThe results of the present sequential approach to management of posterior glenoid defects by the 3 modalities were acceptable. The present MBP-assisted bone-grafting procedure is an effective treatment for cases of shoulder arthropathy with severe posterior glenoid defects. Angulated ring grafting around the central peg may yield equally acceptable results, although its graft-incorporation rate requires further follow-up. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.